---
title: "Maccura: The company has not yet engaged in the layout of stem cell therapy"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/244991437.md"
description: "On June 18th, Maccura stated on the interactive platform that the company focuses on independent research and development, production, and sales of in vitro diagnostic products and services, and has not yet involved itself in the layout of stem cell therapy"
datetime: "2025-06-18T01:10:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/244991437.md)
  - [en](https://longbridge.com/en/news/244991437.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/244991437.md)
generator: "portal-rs"
---

# Maccura: The company has not yet engaged in the layout of stem cell therapy

On June 18th, Maccura stated on the interactive platform that the company focuses on the independent research and development, production, and sales of in vitro diagnostic products and services, and has not yet involved itself in the layout of stem cell therapy

### Related Stocks

- [300463.CN](https://longbridge.com/en/quote/300463.CN.md)

## Related News & Research

- [Guangdong Dtech shareholders to vote Sept. 15 on ending Rongcheng Hong Kong auditor engagement](https://longbridge.com/en/news/296359557.md)
- [Orkla Non-GAAP EPS of NOK 1.60, revenue of NOK 16.7B](https://longbridge.com/en/news/296456178.md)
- [Vow ASA GAAP EPS of NOK 0.02, revenue of NOK 252.9M](https://longbridge.com/en/news/296331370.md)
- [Aditya Birla Capital gains 2.5% after gold loan entry, plans 1,000 branches](https://longbridge.com/en/news/296432637.md)
- [Kona BidCo raises Zalaris stake to 87.34% after buying 2,337 shares at NOK 100 apiece](https://longbridge.com/en/news/296256150.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**